Appointment of Silvère Lucquin as Chief Executive Officer of Okomera
Okomera announces the appointment of Silvère Lucquin as Chief Executive Officer, effective 8 September 2025. He succeeds Sidarth Radjou, who is departing to pursue new professional opportunities. The company thanks Sidarth for his leadership and wishes him continued success.
Silvère brings more than a decade of experience across MedTech and life science tools, with a consistent track record of scaling organizations at the nexus of healthcare and innovation. Most recently, as Chief Operating Officer at Ganymed Robotics, he helped shape corporate strategy, accelerate growth, and lead key initiatives spanning human resources, business modeling, industrial partnerships, and product development.
Before Ganymed Robotics, he held pivotal roles at Aditlys Medical, guiding the spin-off and early company structuring, and at CorWave, where he became the first employee, led major development efforts, and contributed to the company’s expansion through two financing rounds (Series A and B).
An engineer by training, Silvère is a graduate of École Polytechnique (France) and Imperial College London, and he holds an MBA from INSEAD. This combination of technical expertise and business acumen positions him to steer Okomera as it expands its impact on cancer research with innovative technologies.
“We are excited to welcome Silvère as CEO,” said Richard Eglen, Chair of the Okomera Board. “His strategic vision, operational leadership, and commitment to medical innovation make him the ideal person to guide Okomera into its next stage of growth and achievement.”
“Okomera stands at a pivotal moment, built on a solid foundation and driven by a mission to push forward global cancer research,” said Silvère Lucquin. “I am eager to collaborate with the dedicated Okomera team to build on past successes, strengthen partnerships, and speed up the development of groundbreaking solutions for researchers worldwide.”
With Silvère’s leadership, Okomera reaffirms its commitment to advancing technologies that empower scientists and accelerate breakthroughs, helping the global research community drive progress against cancer.
About Okomera
Okomera is a Paris-based life science tools company advancing oncology research through state-of-the-art technologies that integrate microfluidics, cellular biology, and artificial intelligence. The company focuses on organoid screening platforms designed to help researchers accelerate discovery and develop more effective treatments for cancer.
